Is Balaxi Pharmaceuticals a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Balaxi Pharmaceuticals Ltd is a average quality company .

Is Balaxi Pharmaceuticals undervalued or overvalued?

The key valuation ratios of Balaxi Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone .

What is Balaxi Pharmaceuticals share price return in the past 10 years?

Data is not available for this company

Is Balaxi Pharmaceuticals a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Balaxi Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Balaxi Pharmaceuticals?

The latest standalone P/E ratio of Balaxi Pharmaceuticals as of 01-Jan-1970 is 78.20.

What is the P/B ratio of Balaxi Pharmaceuticals?

The latest standalone P/B ratio of Balaxi Pharmaceuticals as of 01-Jan-1970 is 5.12.

What is the 52-week high and low of Balaxi Pharmaceuticals?

The 52-week high of Balaxi Pharmaceuticals is Rs. 0.00 and the 52-week low is Rs. 0.00.

Balaxi Pharmaceuticals Ltd - Stock Valuation and Financial Performance

Name: Balaxi Pharmaceuticals
Brand: Balaxi Pharmaceuticals

BSE: 0 | NSE: BALAXI | Trading | Small Cap

Place order

BSE Share Price
Not Listed

10 Year X-Ray of Balaxi Pharma.:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
ROCE % ⓘ	13.5%	3.9%	-1.5%	-5.1%	-39.6%	79.7%	38.8%	37.7%	24.1%	15.4%	-
Value Creation Index ⓘ	0.0	-0.7	-1.1	-1.4	-3.8	4.7	1.8	1.7	0.7	0.1	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	0.1	0.1	0.1	0	0	13.6	45.6	86.9	101	108	85
Sales YoY Gr.	-	-14.3%	-58.3%	-100%	NA	NA	235.5%	90.4%	16.6%	6.8%	-
Adj EPS ⓘ	1.6	0.2	-0.3	-0.6	-2.5	6.7	6.1	14	12.8	11.9	7.4
YoY Gr.	-	-84.5%	-208.3%	NA	NA	NA	-8.3%	129.3%	-8.8%	-6.6%	-
BVPS (₹) ⓘ	11.1	10.6	10.4	7.7	5.1	11.6	28.1	43.3	57.9	80.4	113.1
Adj Net Profit ⓘ	0.1	0.1	-0.1	-0.2	-0.8	2	6.1	14	12.8	12.1	8
Cash Flow from Ops. ⓘ	-0.2	0.2	0	-0.1	-0.7	-1.5	-14.4	13.5	8.9	-7.1	-
Debt/CF from Ops. ⓘ	-0.8	0	-5.8	0	0	0	0	0.3	0.2	-1.5	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	109.4%	NA	33.3%	6.8%
Adj EPS ⓘ	25.4%	NA	25%	-6.6%
BVPSⓘ	24.6%	73.5%	41.9%	38.8%
Share Price	-	52.1%	-0.1%	4.6%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
Return on Equity % ⓘ	14.2	3.6	-2.5	-6.4	-39.6	79.7	38.6	39.2	25.2	16.2	7.7
Op. Profit Mgn % ⓘ	76.5	36.4	-145.1	0	0	12	19	21.9	17.1	15.6	12.2
Net Profit Mgn % ⓘ	76.1	58.9	-169.2	0	0	14.9	13.4	16.1	12.6	11.2	9.7
Debt to Equity ⓘ	0.2	0	0.1	0	0	0	0	0.1	0	0.1	-
Working Cap Days ⓘ	879	1,036	1,827	0	0	80	160	173	193	237	217
Cash Conv. Cycle ⓘ	369	-253	-338	0	0	39	103	103	108	154	135

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 33.33%

Return on Equity has declined versus last 3 years average to 7.70%

Sales growth is not so good in last 4 quarters at -11.19%

Latest Financials - Balaxi Pharmaceuticals Ltd.

	Standalone	Consolidated
TTM EPS (₹)	7.4	-4.7
TTM Sales (₹ Cr.)	84.6	262
BVPS (₹.) ⓘ	113.1	179.4
Reserves (₹ Cr.) ⓘ	114	187
P/BV ⓘ	5.12	3.22
PE ⓘ	78.20	0.00

From the Market
52 Week Low / High (₹)	0.00 / 0.00
All Time Low / High (₹)	- / -
Market Cap (₹ Cr.)	639
Equity (₹ Cr.)	11
Face Value (₹)	10
Industry PE ⓘ	77.6

Management X-Ray of Balaxi Pharma.:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Balaxi Pharma.

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Balaxi Pharma.

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Sales	0	0	0	0	0	14	46	87	101	108
Operating Expenses ⓘ	0	0	0	0	1	12	37	68	84	91
Manufacturing Costs	0	0	0	0	0	0	0	0	0	0
Material Costs	0	0	0	0	0	10	33	63	77	82
Employee Cost	0	0	0	0	0	1	2	2	3	4
Other Costs ⓘ	0	0	0	0	1	1	2	3	4	5
Operating Profit ⓘ	0	0	0	0	-1	2	9	19	17	17
Operating Profit Margin (%)	76.5%	36.4%	-145.0%	-	-	11.5%	18.9%	21.9%	17.1%	15.6%
Other Income ⓘ	0	0	0	0	0	1	1	2	3	7
Interest ⓘ	0	0	0	0	0	0	0	0	0	1
Depreciation ⓘ	0	0	0	0	0	0	0	0	0	1
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	0	0	0	0	-1	2	9	21	20	22
Tax ⓘ	0	0	0	0	0	0	3	5	5	6
Profit After Tax	0	0	0	0	-1	2	6	15	15	16
PAT Margin (%)	76.7%	82.7%	-169.0%	-	-	14.5%	14.2%	17.4%	14.5%	15.0%
Adjusted EPS (₹)	1.6	0.3	-0.3	-0.6	-2.5	6.5	6.5	15.1	14.7	15.9
Dividend Payout Ratio (%)	64%	89%	0%	0%	0%	0%	0%	0%	3%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Equity and Liabilities
Shareholders Fund	1	3	3	2	2	4	28	43	58	82
Share Capital ⓘ	1	3	3	3	3	3	10	10	10	10
Reserves ⓘ	0	0	0	-1	-1	0	18	33	48	72
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	0	0	0	0	0	0	0	4	2	11
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	0	0	0	0	0	0	0	4	2	11
Trade Payables	0	0	0	0	0	2	7	17	16	17
Others Liabilities ⓘ	0	0	0	0	0	1	3	6	6	20
Total Liabilities ⓘ	1	4	4	2	2	6	38	69	82	130
Fixed Assets
Gross Block	0	0	0	0	0	0	0	1	3	9
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	1
Net Fixed Assetsⓘ	0	0	0	0	0	0	0	1	2	8
CWIP ⓘ	0	0	0	0	0	0	0	0	1	3
Investmentsⓘ	0	3	3	0	0	0	0	20	20	20
Inventories	0	0	0	0	0	0	1	0	0	1
Trade Receivables	0	0	0	0	0	5	31	48	52	78
Cash Equivalents	1	0	0	2	2	0	4	0	1	18
Others Assetsⓘ	0	0	0	0	0	0	2	0	7	2
Total Assets ⓘ	1	4	4	2	2	6	38	69	82	130

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Cash Flow From Operating Activity ⓘ	0	0	0	-1	-2	-14	13	9	-7
PBT ⓘ	0	0	0	-1	2	9	21	20	22
Adjustment ⓘ	0	0	0	0	0	0	0	0	1
Changes in Working Capital ⓘ	-0	0	0	0	-4	-23	-5	-5	-25
Tax Paid ⓘ	0	0	0	0	0	-1	-2	-6	-5
Cash Flow From Investing Activity ⓘ	0	-3	3	0	0	0	-20	-7	-2
Capex	0	0	0	0	0	0	-1	-2	0
Net Investments	0	-3	3	0	0	0	-19	0	0
Others ⓘ	0	0	0	0	0	0	0	-5	-2
Cash Flow From Financing Activityⓘ	0	2	0	0	0	18	3	-2	26
Net Proceeds from Shares ⓘ	0	2	0	0	0	18	0	0	18
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	0	0	0	0	0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0	0	0	0	4	-2	9
Net Cash Flow ⓘ	0	-1	2	-1	-2	3	-3	0	17

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Ratios
ROE (%)	14.3	5.11	-2.52	-6.37	-39.69	77.47	41.07	42.42	29	23.22
ROCE (%)	18.55	7.68	-2.11	-4.69	-39.69	96.22	58.38	55.42	37.14	28.22
Asset Turnover Ratio	0.12	0.05	0.01	0	0	3.49	2.07	1.63	1.34	1.02
PAT to CFO Conversion(x)	N/A	N/A	N/A	N/A	N/A	-1	-2.33	0.87	0.6	-0.44
Working Capital Days
Receivable Days	738	436	35	0	0	147	147	167	181	220
Inventory Days	0	0	0	0	0	0	7	2	0	5
Payable Days	0	0	0	0	0	39	50	68	77	73

Balaxi Pharmaceuticals Ltd Stock News

Balaxi Pharmaceuticals Ltd FAQs

What is the share price of Balaxi Pharma.?

Company share prices are keep on changing according to the market conditions. The closing price of Balaxi Pharma. on 01-Jan-1970 05:30 is ₹0.00.

What is the market cap of Balaxi Pharma.?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Balaxi Pharma. stood at ₹638.6.

What is the P/E ratio of Balaxi Pharma.?

The latest P/E ratio of Balaxi Pharma. as of 01-Jan-1970 05:30 is 78.20.

What is the P/B ratio of Balaxi Pharma.?

The latest P/B ratio of Balaxi Pharma. as of 01-Jan-1970 05:30 is 5.12.

What is the 52-week high and low of Balaxi Pharma.?

The 52-week high of Balaxi Pharma. is ₹0.00 and the 52-week low is ₹0.00.

What is the TTM revenue of Balaxi Pharma.?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Balaxi Pharma. is ₹84.64 ( Cr.) .

About Balaxi Pharmaceuticals Ltd

Balaxi Pharmaceuticals Limited is a branded IPR-based pharmaceutical Company focusing on frontier markets, with a vast and growing portfolio of drugs across multiple therapeutic segments. Its markets extend across the continents of Americas, Africa and the Caribbean islands. It is a dynamic and responsible company, with a rich and growing portfolio of branded and generic medicines and consumer products.

Business area of the company

The company is engaged in the business of international wholesale trading of Pharmaceuticals, Builders Hardware and FMCG products

History and Milestones

2003-07

Commenced Pharmaceutcal business by supplying white labeled products to customers in Africa.
Sourcing was from WHO GMP certified plants based in India.

2008-10

Created frontend presence for its Pharmaceutical Business by setting up 1st wholesale depot in Angola in 2008.

2011-13

Started sourcing pharmaceutical from WHO GMP certified manufacturers in China by setting up an office in China in 2011.
Opened first wholesale depot for its ancillary business in Angola.

2014-16

In 2014, the group expanded its pharmaceutical business in Angola by setting up its 12th wholesale depot and a central distribution warehouse.
Made in-roads in Dominican Republic pharmaceutical market, submitted technical dossiers for securing product registrations and opened a central distribution warehouse.

2017-19

Set-up central distribution warehouse in Guatemala marking the entry of Balaxi into its third geography.
Leveraged the vast on-ground infrastructure in Angola by entering branded consumer goods products business in 2019.

2020